SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is drawing attention amid a selloff in AI infrastructure stocks and concerns that its heavy debt load and costly financing could constrain growth. Traders are split between warnings about dilution and default risk and bullish arguments about AI-compute demand, with Goldmans upgrade and ARKs purchases cited as counterpoints that have not settled the debate.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention as its steep post-IPO selloff continues, with traders citing upcoming share unlocks, reported insider sales, a TD Cowen downgrade and concerns about OpenAI customer concentration and competition from Nvidia. Others argue the decline is overdone, pointing to Cerebras AI-chip technology and potential demand, while broader weakness in AI and semiconductor stocks adds pressure.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcoms sharp underperformance amid a semiconductor selloff has fueled debate over AI spending sustainability and financing risks, with traders also citing CEO Hock Tans casino remarks as a drag on sentiment. Some see the decline as a buying opportunity, while others fear the AI trade is losing momentum.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is drawing attention amid a steep selloff and worries that its debt-funded AI data-center expansion, heavy capital spending, and weak free cash flow may be difficult to finance as credit costs rise and inflation fuels rate concerns. Bears question whether its backlog and AI demand will translate into cash flow, while bulls argue Oracles cloud business and contracted demand make the pullback an opportunity.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is drawing attention amid a sharp AI/neocloud selloff fueled by concerns about financing, debt exposure and whether infrastructure spending will earn adequate returns. Traders are divided over whether the rebound is an oversold relief move or a pause before further declines, with some arguing Nebius is better positioned than more leveraged peers.

Aventus Network

Aventus is drawing attention after the team disclosed that an attacker exploited a code vulnerability to mint and sell AVT, contributing to a sharp selloff; the team says the flaw is patched and the attacker has exited, but no proceeds have been recovered. Traders are split between betting on a thin-book rebound and worrying about continued selling, concentrated holdings, and token-supply changes.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celesticas sharp, volatile pullback after a recent rally has traders debating whether upcoming earnings and continued AI data-center demand can revive the stock. Optimists expect another strong report, while others point to semiconductor-sector weakness and lingering dilution concerns from the equity offering as headwinds.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech and semiconductor rebound after the AI-related selloff has lifted QQQ, with traders debating whether it marks a durable recovery or a short-lived relief bounce. Upcoming megacap earnings and concerns about AI spending, oil prices, and inflation are keeping sentiment divided.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is drawing attention amid a choppy rebound after a tech-led selloff, with traders debating whether the AI- and megacap-led bounce ahead of major earnings signals stabilization or is a temporary rally. Caution over weak market breadth, AI investment and debt concerns, and geopolitical risks contrasts with calls to buy dips and expectations of further gains.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealths third-quarter earnings beat and raised 2026 outlook, supported by improved medical-cost controls, are driving attention as traders debate whether the results signal a durable turnaround. The reaction has been volatile: bullish traders welcome the recovery, while others question why the shares initially faded despite the strong report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Veru (VERU) Q3 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

This Small-Cap Biotech Just Soared Over 160% — What Is The Novo Nordisk Connection?

Equity

Veru will evaluate enobosarm alongside Novo Nordisk’s Wegovy in the Phase 2b PLATEAU trial in older adults with obesity.

Earnings call transcript: Veru Inc Q2 2026 shows improved financials

Others

Veru (VERU) Q1 2026 Earnings Call Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

A Look Ahead: Veru's Earnings Forecast

Top Wall Street Forecasters Revamp Veru Expectations Ahead Of Q4 Earnings

Veru Announces Novel Modified-Release Oral Formulation for Enobosarm 

VERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines and treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. The company was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1971 and is headquartered in Miami, FL.

Veru Inc

Neutral Sentiment

<ul class="summary-bullets"><li>Veru stated in a regulatory filing that it will sponsor and conduct the Phase 2b PLATEAU study, while Novo Nordisk will provide Wegovy at no cost for use in the trial.</li><li>It will also share study-related updates with Novo Nordisk, including information on trial design, protocol amendments, and safety data.</li><li>The company said it will retain full global development and commercialization rights to enobosarm.</li></ul><p>Shares of Veru Inc. (VERU) soared more than 160% in Thursday morning’s trade after the company announced that it had entered into a clinical supply agreement with Novo Nordisk AS (NVO).</p><p>Under the agreement, Veru will evaluate enobosarm alongside Novo Nordisk's Wegovy in the Phase 2b PLATEAU trial in older adults with obesity.</p><p><a href="https://stocktwits.com/symbol/VERU">Veru shares</a> were up more than 158% during Thursday morning’s trade after paring some of the gains.</p><h2 class="st-heading-2">VERU Retains Global Rights To Enobosarm</h2><p>Veru stated in a filing with the U.S. Securities and Exchange Commission (SEC) that it will sponsor and conduct the Phase 2b PLATEAU study, while Novo Nordisk will provide Wegovy at no cost for use in the trial.</p><p>Veru will also share study-related updates with Novo Nordisk, including information on trial design, protocol amendments, and safety data. The company said it will retain full global development and commercialization rights to enobosarm.</p><p>Veru also granted Novo Nordisk a right of first negotiation for any future agreement involving enobosarm in combination with Novo Nordisk GLP-1 therapies, including Wegovy.</p><h2 class="st-heading-2">Canaccord Sees NVO Deal As Major Validation</h2><p>According to TheFly, Canaccord described the Novo Nordisk agreement as a significant milestone for Veru, saying it validates interest in enobosarm from one of the leading players in the obesity market.</p><p>The firm added that it continues to view Veru's clinical data as compelling and believes enobosarm could emerge as a key differentiator in obesity treatment.</p><p>Canaccord reiterated its ‘Buy’ rating and $25 price target on the stock.</p><h2 class="st-heading-2">What Is VERU's Phase 2b PLATEAU Study About?</h2><p>The Phase 2b PLATEAU trial is evaluating Veru's enobosarm in approximately 200 adults aged 65 and older with obesity who are beginning treatment with Wegovy.</p><p>The study aims to determine whether enobosarm can preserve muscle mass and physical function, helping patients overcome the weight-loss plateau often seen with GLP-1 therapies.</p><p>Veru expects interim data on lean mass and fat mass in the first quarter of 2027, with topline results anticipated in the fourth quarter of 2027.</p><h2 class="st-heading-2">How Did Retail Traders React To VERU Stock?</h2><p>Retail sentiment on Stocktwits around Veru trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.</p><p><a href="https://stocktwits.com/symbol/VERU">VERU stock</a> is up 154% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/VERU">NVO stock</a> is down 14%. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 27% over the past 12 months, while the Vanguard Extended Market Index Fund ETF (VXF) is up 29%.</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spacex-ai-revenue-soar-100-times-322b-2030-spcx-ipo-roadshow/cZ0ZKosReyw"><strong>SpaceX's AI Revenue Could Eclipse Starlink — Goldman Forecasts 100-Fold Surge To $322 Billion By 2030</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Shares of REalloys Inc. surged on Monday (Representative image: Getty Images)

Shares of Veru Inc. (VERU) soared more than 160% in Thursday morning’s trade after the company announced that it had entered into a clinical supply agreement with Novo Nordisk AS (NVO).

Novo Nordisk A/S

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$2.31
Prev Close	$2.30
Open	$2.30
Dividend Yield	0.00%
50-Day Moving Average	$2.54
Beta	1.71
Avg. Volume	201,022.89
PE Ratio	-3.78

52-Week High	$7.33
52-Week Low	$2.05
Market Capitalization	$39.22M
EPS (Annual)	-$1.27
Price to Book	1.39
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

VERU Fundamentals